Genetic Variation in TRAF3IP2 (rs13190932)

Launched by SOUTH VALLEY UNIVERSITY · Jul 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a specific genetic variation, called TRAF3IP2 (rs13190932), may affect people with psoriasis and psoriatic arthritis—conditions that cause red, scaly skin patches and joint inflammation. Researchers want to understand if this genetic difference influences how patients respond to a common treatment called methotrexate, which helps control symptoms.

If you are between 18 and 70 years old, have a confirmed diagnosis of psoriasis or psoriatic arthritis, and are about to start methotrexate treatment, you might be eligible to join. Participants should have moderate to severe skin symptoms and be willing to attend follow-up visits. The study does not include people with other autoimmune diseases, those who are pregnant or breastfeeding, or those with certain health issues like liver or kidney problems. If you join, you can expect to receive methotrexate under medical supervision and have regular check-ins to monitor your condition and how your genes might influence treatment. This research aims to help doctors better tailor treatments based on genetic information in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 -70years .
• • the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.
• • Willingness to participate: Signed informed consent.
• • Initiating methotrexate (MTX) therapy: For prospective cohort.
• • Availability for follow-up: Patients must be willing and able to attend scheduled visit.
• Exclusion Criteria:
• • Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
• • Pregnancy and lactation.
• • Patients currently undergoing immunosuppressive or systemic therapies.
• • Patients with known genetic disorders affect immune system function.
• • Patients with liver or kidney impairment.
• • Patients with allergy or contraindication to methotrexate.
• • Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
• • Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).